Fig. 1From: TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancerClinical trial design, sample collection, and patient outcomes. A Scheme of clinical trial design and sample collection. Patients were eligible if their tumor was ER and PR ≤ 10% by immunohistochemistry and HER2-negative as defined by ASCO/CAP criteria. B Kaplan–Meier estimate of event-free survival (EFS) of all 23 patients. C Kaplan–Meier estimate of EFS according to neoadjuvant treatment. D Kaplan–Meier estimate of overall survival (OS) of all 23 patients; E Kaplan–Meier estimate of OS according to neoadjuvant treatmentBack to article page